Publicacións nas que colabora con Manuel Barreiro de Acosta (44)

2025

  1. Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis.TACRO-TOPIC study of GETECCU

    Journal of Crohn's and Colitis, Vol. 19, Núm. 5

  2. Inter-Rater Disagreements in Applying the Montreal Classification for Crohn's Disease: The Five-Nations Survey Study

    United European Gastroenterology Journal, Vol. 13, Núm. 5, pp. 685-696

  3. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of Telemedicine in Inflammatory Bowel Disease

    Gastroenterologia y Hepatologia, Vol. 48, Núm. 6

  4. Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU

    Digestive and Liver Disease, Vol. 57, Núm. 2, pp. 566-573

2024

  1. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 10

  3. Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial

    Digestive Diseases, Vol. 42, Núm. 6, pp. 600-609

  4. P569 Persistence and safety of upadacitinib in Crohn’s disease and ulcerative colitis in real life: results from a Spanish nationwide study

    Journal of Crohn's and Colitis, Vol. 18, Núm. Supplement_1, pp. i1112-i1113

  5. Persistence, Effectiveness, and Safety of Upadacitinib in Crohn's Disease and Ulcerative Colitis in Real Life: Results From a Spanish Nationwide Study (Ureal Study)

    American Journal of Gastroenterology

  6. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 774-792

2023

  1. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

  2. Is Occupation a Risk Factor for Developing Inflammatory Bowel Disease? A Case–Control Study

    Crohn's and Colitis 360, Vol. 5, Núm. 4

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Radon exposure and inflammatory bowel disease in a radon prone area

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 7, pp. 405-409

  4. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176

  5. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Effectiveness of ustekinumab in fistulising perianal Crohn′s disease refractory or intolerant to anti-TNF

    Journal of Crohn's and Colitis, Vol. 15, Núm. Supplement_1, pp. S419-S420

  2. Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  3. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa — GETECCU) on dysplasia screening in inflammatory bowel disease patients

    Gastroenterologia y Hepatologia, Vol. 44, Núm. 6, pp. 435-447